Dapagliflozin (Forxiga®). HTA ID: 22040

Assessment Status Rapid review complete
HTA ID 22040
Drug Dapagliflozin
Brand Forxiga®
Indication For the treatment of chronic kidney disease
Assessment Process
Rapid review commissioned 08/06/2022
Rapid review completed 14/07/2022
Rapid review outcome A full HTA is not recommended. The NCPE recommends that dapaglifozin not be considered for reimbursement at the submitted price.*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.